The Vanguard Group, Inc. has recently announced that it has increased stake in Matinas Biopharma Holdings Inc (AMEX:MTNB) by 0.39%. After grabbing 8.69 million shares, the institutional investor is now in possession of 33400.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.00% having worth around $1.82 million. Moreover, Geode Capital Management LLC increased its share by 1540.0 to have a control over 1.96 million shares. And Jacobs Levy Equity Management, In raised its holdings to 0.75 million shares by acquiring 0.75 million shares or 0.35% of the stake.
Matinas Biopharma Holdings Inc (MTNB) concluded trading on 12/27/23 at a closing price of $0.24, with 6.07 million shares of worth about $1.46 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.49% during that period and on Wednesday the price saw a gain of about 20.42%. Currently the company’s common shares owned by public are about 217.26M shares, out of which, 210.93M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the MTNB stock and their offered price forecasts bring an average price target of $0.65. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1.00 and could fall to a lowest price of $0.30. The stock’s current price level is 63.08% above of average price target set by the analysts, while a rise to estimated low would result in gain of 20.0% for the stock. However, touching the estimated high of $1.00 would mean a gain of 76.0% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Total Market Index Fund are the top 3 mutual funds which are holding stakes in Matinas Biopharma Holdings Inc Vanguard Total Stock Market ETF is currently holding 6.02 million shares of worth totaling $1.26 million. The company recently came buying 0.0 shares which brought its stake up to 2.77% of the company’s outstanding shares. Vanguard Extended Market Index Fu bought 10020.0 shares, after which its hold over company’s outstanding shares expand to 1.09%, leaving 2.37 million shares with the mutual fund that have a worth of about $0.5 million. Fidelity Total Market Index Fund, after buying 0.39 million shares, have now control over 0.18% of the stake in the company. It holds 0.0 shares of worth $80938.0.
Matinas Biopharma Holdings Inc (AMEX: MTNB) started trading at $0.23, above $0.03 from concluding price of the previous day. Stock saw a price change of 4.88% in past 5 days and over the past one month there was a price change of 18.59%. Year-to-date (YTD), MTNB shares are showing a performance of -51.40% which decreased to -53.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.11 but also hit the highest price of $0.89 during that period. The average intraday trading volume for Matinas Biopharma Holdings Inc shares is 9.36 million. The stock is currently trading 9.23% above its 20-day simple moving average (SMA20), while that difference is up 6.43% for SMA50 and it goes to -24.52% lower than SMA200.
The Vanguard Group, Inc. acquired 8.69 million shares of Matinas Biopharma Holdings Inc having value of about $1.82 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 33400.0 shares in the company valued at close to $8016.0, or have control over 0.39% stake in the company. Matinas Biopharma Holdings Inc (AMEX: MTNB) currently have 217.26M outstanding shares and institutions hold larger chunk of about 12.09% of that. Holding of mutual funds in the company is about 4.68% while other institutional holders and individual stake holders have control over 7.41% and 11.17% of the stake respectively.
The stock has a current market capitalization of $52.79M and its 3Y-monthly beta is at 1.75. It has posted earnings per share of -$0.10 in the same period. It has Quick Ratio of 6.19 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MTNB, volatility over the week remained 10.09% while standing at 10.19% over the month.
Analysts are in expectations that Matinas Biopharma Holdings Inc (MTNB) stock would likely to be making an EPS of -$0.03 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.12 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.03 which is -$0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.02 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -9.60% while it is estimated to decrease by -9.49% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Matinas Biopharma Holdings Inc (MTNB)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
